相关实验视频

Updated: Feb 28, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

在复发性卵巢癌中,拉帕提尼布和帕克利塔塞尔的第一期剂量升级

Connie D Cao¹, Joseph Robert McCorkle², Donglin Yan²

¹Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Markey Cancer Center, Lexington, KY 40536, USA.

|February 27, 2026

概括

这项研究确定了卵巢癌患者的帕克利塔塞尔与拉帕提尼布联合的推第二期剂量. 该组合显示出有前途的安全性和疗效信号,总体响应率为50%.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

通过ABCB1介导的对帕克利塔塞尔的耐药性限制了其在癌症治疗中的有效性.
拉帕提尼布是一种氨酸激酶抑制剂,也抑制了ABCB1,可能克服了对帕克利塔塞尔的耐药性.

研究的目的:

为了确定帕克利塔塞尔和拉帕提尼布组合的推第二阶段剂量 (RP2D).
评估这种组合在患有复发性卵巢癌的患者中的安全性和有效性.

主要方法:

一个使用贝叶斯最佳间隔 (BOIN) 设计的第一阶段剂量升级研究.
患者在每周服用帕克利塔塞尔 (80 mg/m2) 之前48小时接受了脉冲拉帕蒂尼布.
拉帕提尼布剂量从每天两次的750毫克增加到2000毫克.

主要成果:

16名患者是可评估的;接受过3种先前治疗的中位数.
推的第二阶段剂量 (RP2D) 确定为lapatinib 2000 mg 每天两次.
整体响应率 (ORR) 为50%,在RP2D时ORR为71.4%.
常见的不良事件包括腹,白血病和贫血.

结论:

帕克利塔塞尔和拉帕提尼布的组合是安全的,并且在复发的卵巢癌中显示出疗效信号.
RP2D是每周服用80毫克/米2的帕克利塔塞尔和每天两次服用2000毫克的拉帕蒂尼布,在两天前服用.
临床试验注册:NCT04608409. 临床试验注册:NCT04608409. 临床试验注册:NCT04608409.

关键词:

拉帕提尼布 (lapatinib) 是一种治疗方法.帕克利塔克塞尔 (paclitaxel) 是一种药物.再发性卵巢癌的发生.

更多相关视频

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...